Vertex Pharma Files 8-K on Financial Results, Operations
Ticker: VRTX · Form: 8-K · Filed: Feb 5, 2024 · CIK: 875320
Complexity: simple
Sentiment: neutral
Topics: financial-results, operations, 8-K, corporate-filing
TL;DR
**VRTX just dropped an 8-K with financial results, time to check the numbers!**
AI Summary
Vertex Pharmaceuticals Incorporated filed an 8-K on February 5, 2024, to announce its results of operations and financial condition. This filing indicates that the company is providing updated financial information, which is crucial for investors to assess its current performance and future prospects. For shareholders or potential buyers of VRTX stock, this matters because it offers transparency into the company's financial health, influencing investment decisions based on revenue, profit, and growth trends.
Why It Matters
This filing provides investors with critical, up-to-date financial information, allowing them to evaluate Vertex Pharmaceuticals' performance and make informed decisions about their investment in VRTX.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial results and operations, which generally carries a low risk as it provides transparency rather than signaling an adverse event.
Analyst Insight
A smart investor would review the full financial statements and exhibits once they become available to understand the specifics of Vertex Pharmaceuticals' performance and how it aligns with their investment thesis for VRTX.
Key Numbers
- February 5, 2024 — Date of Report (This is the date the earliest event reported in the 8-K occurred, indicating when the financial results were finalized or announced.)
- 000-19319 — Commission File Number (This unique identifier helps track Vertex Pharmaceuticals' filings with the SEC.)
Key Players & Entities
- Vertex Pharmaceuticals Incorporated (company) — the registrant filing the 8-K
- Massachusetts (company) — state of incorporation for Vertex Pharmaceuticals
- 000-19319 (dollar_amount) — Commission File Number
- 04-3039129 (dollar_amount) — I.R.S. Employer Identification No.
- 50 Northern Avenue Boston , Massachusetts 02210 (company) — address of principal executive offices
- 617-341-6100 (dollar_amount) — registrant's telephone number
- February 5, 2024 (date) — Date of Report (Date of earliest event reported)
FAQ
What is the primary purpose of this 8-K filing by Vertex Pharmaceuticals Incorporated?
The primary purpose of this 8-K filing by Vertex Pharmaceuticals Incorporated, dated February 5, 2024, is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as per the Item Information section.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is 'Vertex Pharmaceuticals Incorporated'.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing occurred on 'February 5, 2024', as stated under 'Date of Report (Date of earliest event reported)'.
What is the trading symbol and the exchange on which Vertex Pharmaceuticals' Common Stock is registered?
The trading symbol for Vertex Pharmaceuticals' Common Stock, $0.01 Par Value Per Share, is 'VRTX', and it is registered on 'The Nasdaq Global Select Market'.
Is Vertex Pharmaceuticals Incorporated considered an emerging growth company according to this filing?
No, the filing indicates that Vertex Pharmaceuticals Incorporated is not an emerging growth company, as the box for 'Emerging growth company' is unchecked (☐).
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-02-05 16:09:48
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq G
Filing Documents
- vrtx-20240205.htm (8-K) — 25KB
- ex-991_q42023.htm (EX-99.1) — 241KB
- 0000875320-24-000012.txt ( ) — 416KB
- vrtx-20240205.xsd (EX-101.SCH) — 2KB
- vrtx-20240205_lab.xml (EX-101.LAB) — 24KB
- vrtx-20240205_pre.xml (EX-101.PRE) — 12KB
- vrtx-20240205_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 5, 2024, we issued a press release in which we reported our consolidated financial results for the three and twelve months ended December 31, 2023. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description of Document 99.1 Press Release Dated February 5 , 202 4 . 104 Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: February 5, 2024 /s/ Jonathan Biller Jonathan Biller Executive Vice President, Chief Legal Officer